PTC Therapeutics, Inc. (PTCT) on Decifer

Why it ranks here

• It earns strong returns on the money it puts to work, around 33% and those returns have been improving.
• Revenue is growing about 115% a year, profits grew 281% over the past year, and growth is speeding up, not slowing down.
• It keeps a high share of every sale as profit, and that has stayed steady over the years, a sign of real pricing power, with profitability widening as it grows.
• and has the balance sheet to fund its growth.
• We do not have a clean read on how it is run yet.
• Our durability check found pressure on this name, which costs it a few points.
• Its profit margin and growth are both unusually high right now compared to its own history, the kind of combination that often fades once conditions normalize.

The current read

The evidence on PTCT lines up on the supportive side: the intelligence feed flags this name as connected to what is moving markets now. The independent signals we track are telling the same story.

Themes

• Next-Gen Genetic & RNA/Antibody Therapeutics: Platform breakthroughs in RNA interference, redosable gene therapy and antibody engineering are converting once-undruggable and orphan targets into commercial therapies.

Read the full PTCT research brief · See all quality rankings

Intelligence data powered by Decifer. Not financial advice. For informational purposes only.